Suchergebnisse - "Blumenberg, Viktoria"

PubPharm (36)

1

Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy

enthalten in: European journal of nuclear medicine and molecular imaging | 2024

von Voltin, C. | Paccagnella, A. | Winkelmann, M. | +26

2

Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy

enthalten in: Annals of hematology | 2024

von Winkelmann, M. | Blumenberg, V. | Rejeski, K. | +11

3

Recent Bendamustine Treatment Before Apheresis Has a Negative Impact on Outcomes in Patients With Large B-Cell Lymphoma Receiving Chimeric Antigen Receptor T-Cell Therapy

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Iacoboni, G. | Navarro, V. | Martín-López, A. | +21

4

Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy

enthalten in: European journal of nuclear medicine and molecular imaging | 2023

von Voltin, C. | Paccagnella, A. | Winkelmann, M. | +26

5

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL

enthalten in: Blood advances | 2023

von Blumenberg, V. | Busch, G. | Baumann, S. | +24

6

Modification of Lugano criteria by pre-infusion tumor kinetics improves early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy

enthalten in: Journal for immunotherapy of cancer | 2023

von Winkelmann, M. | Blumenberg, V. | Rejeski, K. | +11

7

Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion

enthalten in: Science advances | 2023

von Rejeski, K. | Perez, A. | Iacoboni, G. | +23

8

Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy

enthalten in: Cytotherapy | 2023

von Winkelmann, M. | Blumenberg, V. | Rejeski, K. | +11

9

Inferior Outcomes of EU Versus US Patients Treated With CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma : Association With Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use

enthalten in: HemaSphere | 2023

von Bücklein, V. | Perez, A. | Rejeski, K. | +24

ErratumIn: Hemasphere. 2023 Oct 31;7(11):e982. - PMID 37920708

10

Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy

enthalten in: Cancer immunology research | 2023

von Rejeski, K. | Cordas Dos Santos, D. | Parker, N. | +14

CommentIn: Cancer Immunol Res. 2023 Jun 2;11(6):704. - PMID 37264818